Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Fraunhofer ITMP is part of the EU-funded COVend consortium, which has now announced the enrolment of first patients in the IXION 2.0 clinical trial at the Goethe University Hospital Frankfurt. Following a strategic change in the project's objective in light of the evolving dynamics of COVID-19, the study aims to investigate the potential benefits of the innovative therapeutic agent FX06 for acute respiratory distress syndrome (ARDS) patients.

Fraunhofer, DESY, Hereon and EMBL sign MoU for closer collaboration. Fraunhofer ITMP participates in the health area and already brought this cooperation to life with the “Fraunhofer at DESY: Focus on BioMed” workshop on November 9th 2023. The joint proposal on “The role of antibiotic influx and efflux in antimicrobial resistance of Gram-negative bacteria” from ITMP (experiment design, probes), IAP-CAN (nanoparticle markers) and DESY (imaging) has been awarded as one of the pilot projects.

The Summer School of the Innovation Center TheraNova took place in Darmstadt on September 11 and 12, 2023. Invited speakers reported on various aspects of the translation of cell and gene therapies into clinical application. Participants had the opportunity to exchange information on their projects’ progress, take part in an excursion to the European Space Agency ESA, engage in a workshop on the topic of intellectual property, and learn about spin-offs and entrepreneurship in an open roundtable discussion with startup founders.